Ischemic Heart Disease News and Research

RSS

Results of M118 EMINENCE clinical trial published in Circulation

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that the results of the M118 EMINENCE clinical trial have published in Circulation.

8 Apr 2010

Agent Orange exposure: VA adds three new illnesses to list of health problems

Well over 100,000 Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to qualify for disability pay under a proposed regulation published by the Department of Veterans Affairs (VA) that adds three new illnesses to the list of health problems found to be related to Agent Orange and other herbicide exposures.

27 Mar 2010

Research finds inverse association between supine systolic BP and acute chest pain

New research finds that there is an inverse association between the level of supine (lying face up) systolic blood pressure measured on admission to an intensive care unit for acute chest pain and risk of death at one year, with those patients having high systolic blood pressure having a better prognosis after a year, according to a study in the March 24/31 issue of JAMA.

24 Mar 2010

Proper treatment can help control psoriasis in most cases

For the approximately 7.5 million Americans affected by psoriasis, the thick, red, scaly, itchy plaques it causes only scratch the surface when it comes to the overall implications of this disease. Now, ongoing research linking psoriasis to other serious medical conditions and the incredible toll it can take on a person's overall quality of life are shifting the way psoriasis is viewed - from a common skin disease to a complex systemic condition.

5 Mar 2010

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

Single or unhappily married men may have an elevated risk of fatal stroke in the coming decades, according to a large study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Menssana Research develops 85% accurate breath test for pulmonary tuberculosis

A new breath test can detect active pulmonary tuberculosis, according to a report to be published in the journal "Tuberculosis."

23 Feb 2010

Early life stress could be a risk factor for cardiovascular disease in adulthood

"We think early life stress increases sensitivity to a hormone known to increase your blood pressure and increases your cardiovascular risk in adult life," said Dr. Jennifer Pollock, biochemist in the Vascular Biology Center at the Medical College of Georgia and corresponding author on the study published online in Hypertension.

10 Feb 2010

VA expected to move soon to cover more effects of Agent Orange

The Department of Veterans Affairs may need to pay heavily to treat veterans who have been adversely affected by Agent Orange. McClatchy/Beaufort (S.C.) Gazette report: "The cost of war -- on veterans' health and taxpayer wallets -- will loom a little larger in the new year when the Department of Veterans Affairs issues a final rule to claim adjudicators to presume three more diseases of Vietnam veterans, including heart disease, were caused by exposure to Agent Orange.

8 Jan 2010

Heart Force Medical closes its private, non-brokered financing after raising $4.8 million net

Heart Force Medical Inc., a Vancouver-based company that is developing a non-invasive cardiac assessment, monitoring and screening device, announces today that it has closed its private, non-brokered financing after raising $4.8 million net.

7 Jan 2010

Cardiogenesis submits an IDE for its PHOENIX System

Cardiogenesis Corporation, today announced that it has submitted an IDE (Investigational Device Exemption) to the Food and Drug Administration to initiate a safety and feasibility trial for its PHOENIX System in patients with refractory angina. The PHOENIX handpiece is the first device specifically designed to allow physician-directed tissue stimulation and injections of biologic or pharmacologic agents to pre-determined areas of myocardium.

4 Jan 2010

Researchers use hydrogels to induce significant vasculature growth in areas of damaged tissue

Regenerative medicine therapies often require the growth of functional, stable blood vessels at the site of an injury. Using synthetic polymers called hydrogels, researchers at the Georgia Institute of Technology have been able to induce significant vasculature growth in areas of damaged tissue.

22 Dec 2009

Study examines link between folic acid and cancer incidence

Patients with heart disease in Norway, a country with no fortification of foods with folic acid, had an associated increased risk of cancer and death from any cause if they had received treatment with folic acid and vitamin B12, according to a study in the November 18 issue of JAMA.

18 Nov 2009

Stem cell therapy to treat heart, lung and vascular diseases show positive results

A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.

16 Nov 2009

Prescient Medical to showcase its vProtect Luminal Shield and the vPredict Optical Catheter System

Two products from Prescient Medical -- the vProtect(TM) Luminal Shield and the vPredict(TM) Optical Catheter System -- will be featured at the 3rd Annual Canaccord Adams Cardiovascular Conference. The conference will take place on Tuesday, November 10th in San Francisco, California, and will bring together a select group of med-tech and biotech companies focused on the most important markets in cardiovascular medicine.

9 Nov 2009

$Cardiovascular disease may increase hip fracture incidence$

Cardiovascular disease may increase hip fracture incidence

A study that includes twins finds that the risk of hip fracture was significantly increased following a diagnosis of cardiovascular disease (CVD), with analysis also suggesting a genetic predisposition to the development of CVD and fractures, according to a study in the October 21 issue of JAMA.

26 Oct 2009

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

Harvest Technologies Corp. (www.harvesttech.com) announced today that the Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to commence its BMAC Enhanced CABG Trial. This is a two phase 42-patient 'feasibility' clinical trial using the company's BMAC System to concentrate autologous bone marrow cells to treat patients with congestive heart failure undergoing treatment with coronary artery bypass grafting (CABG) Surgery.

22 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Relying on an independent study by the Institute of Medicine (IOM), Secretary of Veterans Affairs Eric K. Shinseki decided to establish a service-connection for Vietnam Veterans with three specific illnesses based on the latest evidence of an association with the herbicides referred to as Agent Orange.

15 Oct 2009

CIGNA and Prohealth Physicians to implement an enhanced care coordination program

CIGNA and ProHealth Physicians, Inc., have expanded their longstanding relationship by implementing an enhanced care coordination program that includes pay-for-performance provisions and many of the features of a patient-centered medical home program. This is the first program of its kind in Connecticut.

9 Oct 2009

Study: Therapy addition reduces risk of stroke and other cardiovascular events

Data from the independent KYOTO HEART study, presented recently at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, and published online in the European Heart Journal demonstrated the addition of the angiotensin receptor blocker (ARB) Diovan (valsartan) to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative risk reduction in cardiovascular events(1) including stroke, compared to conventional non-ARB treatment regimen.(1)

17 Sep 2009